Earli’s mission is to make cancer a benign experience,
by catching and curing it early.

40% of us will develop cancer in our lifetime.
A third will die from it.
The majority could live,
if we found and treated their cancer early.
Now imagine you could swallow a pill, and a simple urine test will tell you whether you might have an early cancer that needs attention.  A second pill combined with a PET scan then show where the cancer is.  A third pill and a short treatment process eliminate the early cancer. You are cured.  

It’s an audacious goal.

We will start by helping later stage cancer patients receive “live response data” to their treatments directly from the cancer, which allows for effective treatment adaptations. Over time, we aspire for earlier and earlier detection and treatment.
40% of us will develop cancer in our lifetime.
A third will die from it.
The majority could live, if we found and treated their cancer early.
Now imagine you could swallow a pill, and a simple urine test will tell you whether you might have an early cancer that needs attention.  A second pill combined with a PET scan then show where the cancer is.  A third pill and a short treatment process eliminate the early cancer. You are cured.  
It’s an audacious goal.
We will start by helping later stage cancer patients receive “live response data” to their treatments directly from the cancer, which allows for effective treatment adaptations. Over time, we aspire for earlier and earlier detection and treatment.

The Science

The search for natural biomarkers shed by cancer into the bloodstream is an exciting concept, but in practice it is exceedingly difficult to find the very small amounts of early cancer cell DNA, with trillions of other similar-looking cell DNA around.
Earli is developing a radically new technique originally from Stanford University. Instead of searching, we force cancer cells to make Synthetic Biomarkers that do not belong in the human body, which are then detectable in blood, urine, or breath. Using a similar technique, we will then localize and ultimately destroy the cancer.
A new era of Synthetic Biomarkers is here.

The Earli Story

Sam Gambhir’s wife Aruna developed breast cancer, and survived it. Then his only 15-year old son Milan developed brain cancer. Meanwhile Sam was urgently searching for new ways to detect and treat cancer, as founder of Stanford’s Canary Center of Early Cancer Detection, and head of Radiology at the Stanford Clinic. Natural cancer biomarkers in blood were promising, but proving elusive. So Sam flipped the problem on its head and came up with a radically new idea. Four years of lab work ensued to make it work in mice.
On Thanksgiving Day, Cyriac Roeding, a successful serial entrepreneur, read Sam’s story and contacted him. He had looked at 200 ideas to find the right next challenge.

Learn More About Us

News

  • Lee Hartwell, former President of the Fred Hutchinson Cancer Research Center, and Nobel Laureate in Medicine, joins Earli Advisory Board.
  • Rob Califf, former FDA Chairman and Verily Advisory Board Member, joins Earli Advisory Board.
  • Earli starts Clinical Advisory Board, with first member Adam Bass from the Dana-Farber Cancer Institute, Harvard Medical School, and Broad Institute, Division of Cellular and Molecular Oncology.
  • Earli signed exclusive IP license agreement with Stanford’s Gambhir Lab.

Join the Earli Team

Earli is looking for the world’s best in cell biology, gene delivery, parallelizing experiments, animal/human trials, and bio AI.
If that’s possibly you, and you like big missions and hard work, *please* let us know.

Contact Us

Are you a potential partner, a journalist, or interested in joining our team?
Or perhaps you just want to say hi.

© Earli Inc.